Organization and Basis of Presentation (Details) - USD ($) |
12 Months Ended | |||
|---|---|---|---|---|
Feb. 23, 2022 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 15, 2023 |
|
| Organization and Basis of Presentation [Line Items] | ||||
| Reclassifications cash flow activity | $ 23,000 | |||
| Offering costs | $ 17,100,000 | $ 18,400,000 | ||
| Convertible preferred stock shares (in Shares) | 5,626,365 | |||
| Proteomedix [Member] | ||||
| Organization and Basis of Presentation [Line Items] | ||||
| Subsidiary owned, percentage | 100.00% | |||
| IPO [Member] | ||||
| Organization and Basis of Presentation [Line Items] | ||||
| Common stock (in Shares) | 2,222,222 | |||
| Public of per share (in Dollars per share) | $ 9 | |||
| Offering costs | $ 2,900,000 | |||
| Onconetix [Member] | ||||
| Organization and Basis of Presentation [Line Items] | ||||
| Equity interest ownership percentage | 100.00% | |||